Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 48, 2016, Pages E7759-E7768

  Spranger, Stefani ^a   Luke, Jason J ^a   Bao, Riyue ^a   Zha, Yuanyuan ^a   Hernandez, Kyle M ^a   Li, Yan ^a   Gajewski, Alexander P ^a   Andrade, Jorge ^a   Gajewski, Thomas F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Checkpoint blockade; Immunotherapy; Neoantigens; T cell inflammation; Tumor microenvironment

Indexed keywords

ANTIGEN; CANCER TESTIS ANTIGEN; CD8 ANTIGEN; DIFFERENTIATION ANTIGEN; EPITOPE; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; HLA A ANTIGEN; TUMOR ANTIGEN;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DENDRITIC CELL; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; INFLAMMATION; LYMPHOCYTIC INFILTRATION; METASTATIC MELANOMA; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; SOLID TUMOR; SOMATIC MUTATION; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; GENE EXPRESSION; GENETICS; IMMUNOLOGY; MELANOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY; SKIN TUMOR; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, NEOPLASM; GENE EXPRESSION; HLA-A ANTIGENS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; SKIN NEOPLASMS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 84999098073     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1609376113     Document Type: Article

References (37)

1. Topalian SL, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443-2454.
2. Larkin J, et al. (2015) Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23-34.
3. Robert C, et al.; KEYNOTE-006 investigators (2015) Pembrolizumab versus Ipilimumab in advanced melanoma. N Engl J Med 372(26):2521-2532.
4. Tumeh PC, et al. (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568-571.
5. Spranger S, et al. (2013) Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 5(200):200ra116.
6. Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14(10):1014-1022.
7. Spranger S, et al. (2014) Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2:3.
8. Harlin H, et al. (2009) Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 69(7):3077-3085.
9. Chen J, et al. (2014) Predictive immune biomarker signatures in the tumor microenvironment of melanoma metastases associated with tumor-infiltrating lymphocyte (TIL) therapy. J Immunother Cancer 2(Suppl 3):P243.
10. Spranger S, Bao R, Gajewski TF (2015) Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523(7559):231-235.
11. Peng W, et al. (2016) Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov 6(2):202-216.
12. Snyder A, et al. (2015) Genetics and immunology: Reinvigorated. OncoImmunology 4(10):e1029705.
13. Gros A, et al. (2016) Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med 22(4):433-438.
14. McGranahan N, et al. (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351(6280):1463-1469.
15. Snyder A, et al. (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371(23):2189-2199.
16. Gajewski TF, Louahed J, Brichard VG (2010) Gene signature in melanoma associated with clinical activity: A potential clue to unlock cancer immunotherapy. Cancer J 16(4):399-403.
17. Seiwert TY, et al. (2015) Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. J Clin Oncol 33, (suppl; abstr 6017).
18. Sweis RF, et al. (2016) Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol Res 4(7):563-568.
19. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanović S (1999) SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 50(3-4):213-219.
20. Martini M, et al. (2010) IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine 28(20):3548-3557.
21. Gajewski TF, Fallarino F, Ashikari A, Sherman M (2001) Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res 7(3 Suppl):895s-901s.
22. Roberts EW, et al. (2016) Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 30(2):324-336.
23. Aliberti J, et al. (2000) CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ dendritic cells. Nat Immunol 1(1):83-87.
24. Salerno EP, Olson WC, McSkimming C, Shea S, Slingluff CL, Jr. (2014) T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. Int J Cancer 134(3):563-574.
25. Borghaei H, et al. (2015) Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17):1627-1639.
26. Brahmer J, et al. (2015) Nivolumab versus Docetaxel in advanced squamous-Cell non-small-cell lung cancer. N Engl J Med 373(2):123-135.
27. Motzer RJ, et al.; CheckMate 025 Investigators (2015) Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803-1813.
28. Hamanishi J, et al. (2015) Safety and antitumor activity of anti-PD-1 antibody, Nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33(34):4015-4022.
29. Ward JP, Gubin MM, Schreiber RD (2016) The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer. Adv Immunol 130:25-74.
30. Woo SR, et al. (2014) STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41(5):830-842.
31. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N (2015) Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160(1-2):48-61.
32. Auton A, et al.; 1000 Genomes Project Consortium (2015) A global reference for human genetic variation. Nature 526(7571):68-74.
33. Wilks C, et al. (2014) The Cancer Genomics Hub (CGHub): Overcoming cancer through the power of torrential data. Database (Oxford) 2014:bau093.
34. Li H, et al.; 1000 Genome Project Data Processing Subgroup (2009) The Sequence Alignment/Map format and SAMtools. Bioinformatics 25(16):2078-2079.
35. Liu C, et al. (2013) ATHLATES: Accurate typing of human leukocyte antigen through exome sequencing. Nucleic Acids Res 41(14):e142.
36. Bai Y, Ni M, Cooper B, Wei Y, Fury W (2014) Inference of high resolution HLA types using genome-wide RNA or DNA sequencing reads. BMC Genomics 15:325.
37. McLaren W, et al. (2010) Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 26(16):2069-2070.